Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: A retrospective bicentric experience


Por: Melgosa Ramos FJ, García Ruiz R, Mateu Puchades A and Alfageme Roldán F

Publicada: 1 jul 2022 Ahead of Print: 1 may 2022
Resumen:
Hidradenitis suppurativa (HS) is a chronic, inflammatory, and recalcitrant skin disease of the terminal hair follicle. Therapeutic alternatives in HS are limited nowadays. Adalimumab, is the only approved biological treatment for patients with moderate to severe HS, and some patients do not reach an optimal response, or experience a progressive response loss, needing therapeutic alternatives. IL-23 pathway is also involved in HS pathogenesis, so its blockade could contribute to reach disease control. Guselkumab is a monoclonal antibody targeting the p19 subunit of extracellular IL-23, currently approved for psoriasis in adults, and recently some authors have reported its effectiveness in patients with moderate to severe HS refractory to other systemic treatments, becoming a hope for some patients. However adequate dosing and intervals have not been determined yet, so in most published series, doses approved for psoriasis are commonly used. On this topic a retrospective bicentric study including HS patients treated with guselkumab in the dermatologic departments of university hospitals Puerta de Hierro of Majadahonda (Madrid, Spain) and Doctor Peset of Valencia (Valencia, Spain) was conducted. We reported effectiveness, dosage and frequency of administration in the cohort, in order to establish the most effective dosage regimen and to clarify the potential role of guselkumab for this disease.

Filiaciones:
:
 Department of dermatology, University Hospital Doctor Peset of Valencia, Valencia, Spain

:
 Department of dermatology, University Hospital Doctor Peset of Valencia, Valencia, Spain

:
 Department of dermatology, University Hospital Doctor Peset of Valencia, Valencia, Spain

Alfageme Roldán F:
 Department of dermatology, University Hospital Puerta de Hierro of Majadahonda, Madrid, Spain
ISSN: 13960296





DERMATOLOGIC THERAPY
Editorial
Blackwell Publishing Inc., 111 RIVER ST, HOBOKEN 07030-5774, NJ USA, Estados Unidos America
Tipo de documento: Article
Volumen: 35 Número: 7
Páginas:
WOS Id: 000794070100001
ID de PubMed: 35510581
imagen gold

MÉTRICAS